Analyst consensus rating
Iovance Biotherapeutics Analyst Rating: Buy
Direct answer
Iovance Biotherapeutics's consensus rating is Buy.
9 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $10.00.
Forecast evidence checked September 8, 2026.
Get free Iovance Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $8.77
- Average price target
- $10.00
- High price target
- $14.00
- Low price target
- $6.00
- Low target gap
- -31.6%
- Target upside
- +14%
- High target gap
- +59.6%
- Target range width
- 91.2%
- Consensus rating
- Buy
- Analysts
- 9
- Evidence date
- September 8, 2026
- Valid through
- September 15, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Iovance Biotherapeutics?
Iovance Biotherapeutics has a verified Buy consensus. The same dataset has an average price target of $10.00.
How far are Iovance Biotherapeutics's low and high targets from the recorded price?
The low target implies -31.6%, while the high target implies +59.6%.
How many analysts are included in Iovance Biotherapeutics's consensus?
The verified consensus includes 9 analysts.
How is Iovance Biotherapeutics's target upside or downside calculated?
The average target of $10.00 is divided by the recorded price of $8.77, then one is subtracted to produce +14%. This does not guarantee a future return.
When was Iovance Biotherapeutics's analyst forecast verified?
The data was verified on 2026-09-08. The dataset is valid through 2026-09-15.